Abstract: A respirable aqueous pharmaceutical composition comprising a neutralizing affinity binder for a virus binding to angiotensin-converting enzyme 2 (ACE2), a buffer, and a solubilizer.

Abstract: In the invention is provided a polypeptide comprising at least 75 amino acids and having an amino acid sequence having at least 90%, such as at least 95%, 96%, 97, 98%, or 99%, such as 100% sequence identity (% SI) with human Angiotensin-converting enzyme 2 (ACE2) (SEQ ID NO 1), for use in the treatment of COVID19, SARS, or MERS, characterized in that the polypeptide is administered pulmonary and/or nasally. Further is provided the polypeptide for use in reducing the number of active virus particles being exhaled by a treated subject infected by SARS-CoV-2, SARS-CoV, or Mers-CoV. Also a dry powder or an aerosol comprising the polypeptide.

Abstract: A pancreatic cancer detection device, including: a solid surface comprising an antibody bound to the solid surface, the solid surface configured to indicate selective binding between the antibody and one or more target protein(s); and wherein the antibody is configured to selectively bind to the target protein(s). In some examples, the target protein(s) include one or more protein(s) selected from the group consisting of Alpha-1 antitrypsin (A1AT), Alpha-1-acid glycoprotein 1 (AGP1), Apolipoprotein A1 (ApoA1), C1-inhibitor, Complement C2, Complement component 3, Carbohydrate antigen 19-9, Calprotectin, caspase-cleaved cytokeratin-18 (CCK18), Ceruloplasmin, cartilage oligomeric matrix protein, gamma-glutamyl transpeptidase, Haptoglobin, Insulin-like growth factor 1, Insulin-Like Growth Factor Binding Protein 3, Properdin, Serum amyloid A, and Tumor necrosis factor alpha (TNF alpha).

Abstract: Disclosed is a angiogenesis inhibition determining method using MALDI mass spectrometry, and more particularly, relate to a method for detecting whether small molecules are bound with a target protein and for measuring a binding distribution between the small molecules and the target protein by comparing a result of MALDI mass spectrometry with a result of immunofluorescence of the small molecules, which are used as drugs, for the target protein, and for determining as angiogenesis is inhibited in a portion overlapping with a portion where the drug small molecules are present after the MALDI mass spectrometry in the cell or in the biosample including organelles and a portion where the target protein is present after immunofluorescence, as well as for detecting presence or absence and a distribution state of small molecules used as drugs in a sample by using MALDI mass spectrometry.

Abstract: Disclosed is a angiogenesis inhibition determining method using MALDI mass spectrometry, and more particularly, relate to a method for detecting whether small molecules are bound with a target protein and for measuring a binding distribution between the small molecules and the target protein by comparing a result of MALDI mass spectrometry with a result of immunofluorescence of the small molecules, which are used as drugs, for the target protein, and for determining as angiogenesis is inhibited in a portion overlapping with a portion where the drug small molecules are present after the MALDI mass spectrometry in the cell or in the biosample including organelles and a portion where the target protein is present after immunofluorescence, as well as for detecting presence or absence and a distribution state of small molecules used as drugs in a sample by using MALDI mass spectrometry.

Abstract: Methods for producing and using protein/peptide fingerprints, allowing identification and investigation of disease-associated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD), especially for the enzyme MMP12.